Update on attention-deficit/hyperactive disorder treatment;Actualización en el tratamiento del trastorno por déficit de atención/hiperactividad

Revista de Neurologia

Volumn 49, Issue 5, 2009, Pages 257-264

  Loro Lopez M ^a   Quintero, Javier ^b   Garcia Campos N ^a   Jimenez Gomez B ^b   Pando, F ^a   Varela Casal, P ^c   Campos, J A ^a   Correas Lauffer, J ^d  

^a Instituto Neuroconductual de Madrid   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d Universidad Francisco de Vitoria   (Spain)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder (ADHD); CBT; Cognitive rehabilitation; Cognitive behavioral therapy; Methylphenidate; Neurofeedback; Pychostimulants; Treatment

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; METHYLPHENIDATE; REBOXETINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ATTENTION DEFICIT DISORDER; COGNITIVE THERAPY; COMORBIDITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; EPIGASTRIC PAIN; FOOD AND DRUG ADMINISTRATION; GOLD STANDARD; HUMAN; HYPOXIA; INSOMNIA; IRRITABILITY; MIGRAINE; NAUSEA; PSYCHOEDUCATION; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; STOMACH PAIN; TREATMENT PLANNING; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 70349286793     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4905.2009210     Document Type: Review

References (64)

1. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention deficit/hyperactivity disorder. Pediatrics 2000; 105, 1158-1170
2. Barkley RA, Du Paul GJ, Costello A. Stimulants. In Werry JS, Aman MG, eds. Practitioner's guide to psychoactive drugs for children and adolescents. New York: Plenum Medical Books; 1993. p. 205-237
3. IT del Sistema Nacional de Salud 2008; 32: 17-19.
4. Quintero-Gutiérrez del Álamo FJ, Correas-Lauffer J, Quintero-Lumbreras FJ. Trastorno por déficit de atención e hiperactividad a lo largo de la vida. 3 ed. Barcelona: Elsevier-Masson; 2009.
5. The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1088-1096
6. Jensen PS, Hinshaw SP, Swanson JM, Greenhill LL, Conners CK, Arnold LE, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001; 22: 60-77.
7. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56: 1073-1086
8. Conners CK, Epstein JN, March SS, Angold A, Wells KC, Klaric J, et al. Multimodal treatment of ADHD in the MTA; an alternative outcome analysis. J Am Acad Child Adolesc Psychiatry 2001; 40: 159-167 (Pubitemid 32111019)
9. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am 1992; 15: 191-222.
10. Elia J, Borcherding BG, Potter WZ, Mefford IN, Rapoport JL, Keysor CS. Stimulant drug treatment of hyperactivity: biochemical correlates. Clin Pharmacol Ther 1990; 48: 57-66. (Pubitemid 20236203)
11. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am 2000; 9: 573-603.
12. Fernández A, Quintero J, Hornero R, Zuluaga P, Navas M, Gómez C, et al. Complexity analysis of spontaneous brain activity in ADHD: diagnostic implications. Biol Psychiatry 2009; 65: 571-577
13. Barkley RA. Avances en el diagnóstico y la subclasificación del trastorno por déficit de atención/hiperactividad: qué puede pasar en el futuro respecto al DSM-V. Rev Neurol 2009; 48 (Suppl 2): S101-6.
14. Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry 2001; 40: 188-196 (Pubitemid 32111022)
15. Montañés-Rada F, Gangoso-Fermoso AB, Martínez-Granero MA. Fármacos para el trastorno por déficit de atención/hiperactividad. Rev Neurol 2009; 48: 469-481
16. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 2006; 8: 4. (Pubitemid 44541837)
17. Barkley RA. The effects of methylphenidate on the interactions of preschool ADHD children with their mothers. J Am Acad Child Adolesc Psychiatry 1988; 27: 336-341 (Pubitemid 18137260)
18. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol 2004; 24: 24-29 (Pubitemid 38134162)
19. Ramos-Quiroga JA, Bosch-Munsó R, Castells-Cervelló X, Nogueira-Morais M, García-Giménez E, Casas-Brugué M. TDAH en adultos: características clínicas y terapéuticas. Rev Neurol 2006; 42: 600-606
20. Barkley RA. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 1977; 18: 137-165 (Pubitemid 8092156)
21. Cohen NJ, Sullivan J, Minde K, Novak C, Helwig C. Evaluation of the relative effectiveness of methylphenidate and cognitive behavior modification in the treatment of kindergarten-aged hyperactive children. J Abnorm Child Psychol 1981; 9: 43-54. (Pubitemid 11119343)
22. Martín-González R, González-Pérez PA, Izquierdo-Hernández M, Hernández-Expósito S, Alonso-Rodríguez MA, Quintero-Fuentes I, et al. Evaluación neuropsicológica de la memoria en el trastorno por déficit de atención/hiperactividad: papel de las funciones ejecutivas. Rev Neurol 2008; 47: 225-230
23. Rapport MD, DuPaul GJ, Kelly KL. Attention deficit hyperactivity disorder and methylphenidate: the relationship between gross body weight and drug response in children. Psychopharmacol Bull 1989; 25: 285-290
24. Rapport MD, DuPaul GJ. Hyperactivity and methylphenidate: rate-dependent effects on attention. Int Clin Psychopharmacol 1986; 1: 45-52.
25. Douglas VI, Barr RG, Amin K, O'Neill ME, Britton BG. Dosage effects and individual responsivity to methylphenidate in attention deficit disorder. J Child Psychol Psychiatry 1988; 29: 453-475 (Pubitemid 18190309)
26. Whalen CK, Henker B, Granger DA. Social judgment processes in hyperactive boys: effects of methylphenidate and comparisons with normal peers. J Abnorm Child Psychol 1990; 18: 297-316. (Pubitemid 20303342)
27. Satterfield JH, Hoppe CM, Schell AM. A prospective study of delinquency in 110 adolescent boys with attention deficit disorder and 88 normal adolescent boys. Am J Psychiatry 1982; 139: 795-798
28. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409-432 (Pubitemid 126418605)
29. González de Dios J, Cardó E, Servera M. Metilfenidato en el tratamiento del trastorno por déficit de atención e hiperactividad: ¿realizamos una práctica clínica adecuada? Rev Neurol 2006; 43: 705-714
30. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 894-921.
31. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47: 994-1009
32. Pliszka SR, Matthews TL, Braslow KJ, Watson MA. Comparative effects of methylphenidate and mixed salts anfetaminaetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 520-526
33. Mei Z, Grummer-Strawn LM, Thompson D, Dietz WH. Shifts in percentiles of growth during early childhood: analysis of longitudinal data from the California Child Health and Development Study. Pediatrics 2004; 113: 617-627
34. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry 1999; 56: 330-336 (Pubitemid 29165176)
35. San Sebastián-Cabases, J, Quintero-Gutiérrez del Álamo FJ. Tratamiento multimodal del trastorno por déficit de atención con hiperactividad (TDAH). Rev Esp Pediatr 2005; 61: 503-514 (Pubitemid 43241318)
36. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006; 15: 476-495
37. National Institute for Health and Clinical Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults: NICE guideline. September 2008. URL: http://www.nice.org.uk/cg72.
38. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry 2003; 64 (Suppl 11): S3-8. (Pubitemid 37169642)
39. Kratochvil CJ, Michelson D, Newcorn JH, Weiss MD, Busner J, Moore RJ, et al. High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. J Am Acad Child Adolesc Psychiatry 2007; 46: 1128-1137 (Pubitemid 47295924)
40. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety and other disorders. Am J Psychiatry 1991; 148: 564-577
41. Geller D, Donnelly C, López F, Rubin R, Newcorn J, Sutton V, et al. Atomoxetine treatment for pediatrics patients with attention-deficit/ hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 1119-1127 (Pubitemid 47295923)
42. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Child Adolesc Psychiatry 2006; 45: 919-927 (Pubitemid 44126866)
43. Bangs ME, Tausher-Wisniewki S, Polzer J. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolescent Psychiatry 2008; 47: 209-218 (Pubitemid 351158789)
44. Kelsey DK, Summer CR, Casat CD, Coury DL, Quintana H, Saylor KE, et al. Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004; 114: e1-8.
45. Pliszka SR, Lynn C. Revisión del algoritmo para el tratamiento farmacológico del TDAH. J Am Acad Child Adolesc Psychiatry 2006; 45: 6.
46. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D. Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165: 721-730
47. Taylor EA. El niño hiperactivo. Barcelona: Martínez Roca; 1991.
48. Abikoff H, Klein RG. Attention-deficit hyperactivity and conduct disorder: comorbidity and implications for treatment. J Consult Clin Psychol 1992; 60: 881-892
49. Gutiérrez-Moyano Z, Becoña E. Tratamiento de la hiperactividad. Revista Española del Comportamiento 1989; 7: 3-13.
50. Miranda A, Soriano M, Presentación MJ, Gargallo B. Intervención psicoeducativa en estudiantes por déficit de atención con hiperactividad. Rev Neurol Clin 2000; 1: 203-216
51. Ackerman JM. Aplicación de las técnicas del condicionamiento operante en la escuela. Madrid: Santillana; 1988.
52. DuPaul G, Stoner G. ADHD in the schools: assessment and intervention strategies. New York: Guilford Press; 1994.
53. Kendall PC, Panichelli-Mindel SM. Cognitive-behavioral treatments. Abnorm Child Psychol 1995; 23: 107-124
54. Vygotsky L. Pensamiento y lenguaje. Buenos Aires: Pléyade; 1977.
55. Luria AR. Lenguaje y pensamiento. Barcelona: Martínez Roca; 1986.
56. McGuire BE. Computer-assisted cognitive rehabilitation. The Irish Journal of Psychology 1990; 11: 299-308.
57. Fox DJ, Tharp DF, Fox LC. Neurofeedback: an alternative and efficacious treatment for attention deficit hyperactivity disorder. Appl Psychophysiol Biofeedback 2005; 30: 365-373 (Pubitemid 43033260)
58. Lubar JF, Shouse MN. EEG and behavioral changes in a hyperactive child concurrent with training of the sensorimotor rhythm (SMR). A preliminary report. Biofeedback Self Regul 1976; 1: 293-306.
59. Fuchs T, Birbaumer N, Lutzenberger W, Gruzelier JH, Kaiser J. Neuro-feedback treatment for AD/HD in children: a comparison with methylphenidate. Appl Psychophysiol Biofeedback 2003; 28: 1-12.
60. Ríos-Lago M, Muñoz-Céspedes JM, Paúl-Lapedriza N. Alteraciones de la atención tras daño cerebral traumático: evaluación y rehabilitación. Rev Neurol 2007; 44: 291-297 (Pubitemid 350292724)
61. Parenté R, Herrmann D. Retraining cognition: techniques and applications. Maryland: Aspen Publishers; 1996.
62. Ylvisaker M, Coelho C, Kennedy M, Sohlberg M, Turkstra L, Avery J, et al. Reflections on evidence-based practice and rational clinical decision making. J Med Speech Lang Pathol 2002; 10: 25-33. (Pubitemid 36259279)
63. Stefanatos GA, Baron IS. Attention-deficit/hyperactivity disorder: a neuropsychological perspective towards DSM-V. Neuropsychol Rev 2007; 17: 5-38.
64. Quintero J, Rodríguez Quirós J, Correas J, Pérez-Templado J. Aspectos nutricionales en el trastorno por déficit de atención/hiperactividad. Rev Neurol 2009; 49: 307-312